Acucela’s oral DR drug shows potential for reducing retinal thickness

An experimental treatment for proliferative diabetic retinopathy, emixustat hydrochloride, has shown promise in a phase 2 trial, according to a press release by Acucela.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553